Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of AD-209
Condition or disease : hypertension
Age
19 - No limit years
Sex
ALL
Healthy Volunteers
No
Korea University Guro Hospital
Seoul, South Korea
Start Date
May 20, 2024
Primary Completion Date
February 1, 2025
Completion Date
February 1, 2025
Last Updated
May 21, 2024
280
ESTIMATED participants
AD-209
DRUG
AD-2091
DRUG
AD-209 Placebo
DRUG
AD-2091 Placebo
DRUG
Chang Gyu Park, M.D., Ph.D
CONTACT
Lead Sponsor
Addpharma Inc.
NCT05067998
NCT04625569
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions